Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Expenses (2021 - 2025)

InMed Pharmaceuticals' Operating Expenses history spans 5 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 15.77% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $9.2 million, down 3.73%, while the annual FY2025 figure was $9.7 million, 3.83% up from the prior year.
  • Operating Expenses reached $2.3 million in Q4 2025 per INM's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $6.8 million in Q2 2022 to a low of $2.0 million in Q4 2023.
  • Average Operating Expenses over 5 years is $2.8 million, with a median of $2.4 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: crashed 69.64% in 2023, then skyrocketed 37.88% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $4.4 million in 2021, then plummeted by 46.99% to $2.3 million in 2022, then fell by 16.03% to $2.0 million in 2023, then skyrocketed by 37.88% to $2.7 million in 2024, then fell by 15.77% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Operating Expenses are $2.3 million (Q4 2025), $2.2 million (Q3 2025), and $2.4 million (Q2 2025).